

Anders Nykjaer, et al.

U.S. Serial No.: 10/539,443; Filed: June 20, 2005

Amendment in Response to Final Office Action submitted March 23, 2010

Page 2

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-90. (Canceled)

Claim 91. (Previously presented) The method of claim 93, wherein the receptor is exposed to the antibody in an amount of from 1 μ g/kg to about 100 mg/kg per day.

Claim 92. (Canceled)

Claim 93. (Currently amended) A method for inhibiting the binding of ~~a pro-neurotrophin~~ pro-NGF to a sortilin receptor of the ~~Vps10p domain receptor~~ family in an animal, wherein ~~the animal suffers from an injury or dysfunction of the central or peripheral nervous system in need of increased survival of neurons~~, which comprises exposing said receptor to an inhibitorily effective amount of an antibody which binds to an extracellular part of such ~~[[a]]~~ receptor, and thereby inhibits the binding of ~~a pro-neurotrophin~~ pro-NGF to said receptor.

Claim 94. (Previously presented) The method of claim 93, wherein the animal is a human being.

Claims 95-96. (Canceled)

Claim 97. (Previously presented) The method of claim 93, wherein the antibody binds to a peptide comprising amino acid residues 612-740 of SEQ ID NO:1.

Anders Nykjaer, et al.

U.S. Serial No.: 10/539,443; Filed: June 20, 2005

Amendment in Response to Final Office Action submitted March 23, 2010

Page 3

Claim 98. (Previously presented) The method of claim 93, wherein the antibody binds to a peptide comprising amino acid residues 24-77 of SEQ ID NO:1.

Claims 99-100. (Canceled)